Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : Chrs save search
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
Published: 2023-12-26 (Crawled : 21:00) - globenewswire.com
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: 37.61%
H: 1.67%
C: -10.33%
fda approval udenyca system
FDA Roundup: October 31, 2023
Published: 2023-10-31 (Crawled : 21:00) - prnewswire.com
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: -1.49%
H: 5.15%
C: -3.03%
fda
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2023-10-27 (Crawled : 19:00) - globenewswire.com
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
| Email alert
Add to watchlist
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
| Email alert
Add to watchlist
fda approval treatment
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
Published: 2023-09-25 (Crawled : 13:00) - globenewswire.com
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: -2.24%
H: 0.0%
C: -7.11%
udenyca fda license review ongoing application response
FDA Approves UDENYCA® Autoinjector
Published: 2023-03-06 (Crawled : 13:00) - globenewswire.com
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: 2.55%
H: 0.55%
C: -6.49%
udenyca fda
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2022-12-25 (Crawled : 16:20) - globenewswire.com
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
| Email alert
Add to watchlist
treatment fda application license review update
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2022-12-24 (Crawled : 08:20) - globenewswire.com
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
| Email alert
Add to watchlist
treatment fda application license review update
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
Published: 2022-08-02 (Crawled : 00:00) - globenewswire.com
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: 1.2%
H: 6.02%
C: -0.79%
lucentis fda biosimilar
Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
Published: 2022-07-06 (Crawled : 13:00) - biospace.com/
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: 0.12%
H: 5.85%
C: 3.86%
treatment fda resubmission
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
Published: 2022-07-06 (Crawled : 13:00) - biospace.com/
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: 0.12%
H: 5.85%
C: 3.86%
treatment fda resubmission
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
Published: 2022-05-02 (Crawled : 13:20) - biospace.com/
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: -6.26%
H: 8.64%
C: 8.64%
fda response
Junshi Biosciences and Coherus Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
Published: 2022-05-02 (Crawled : 12:00) - biospace.com/
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: -6.26%
H: 8.64%
C: 8.64%
fda response
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
Published: 2021-12-20 (Crawled : 15:00) - biospace.com/
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: 1.85%
H: 1.17%
C: 0.64%
fda fda approval approval
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | $162.93 0.78% 3.1M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal CarcinomaFDA has granted the toripalimab BLA Priority Review with a target action date of April 2022
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | $162.93 0.78% 3.1M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance granted
Polpharma Biologics Group Announces that the Biologics License Application (BLA) Submitted by its Joint Venture Bioeq for its Biosimilar Ranibizumab has Been Accepted for Review by the U.S. Food and Drug Administration (FDA)
Published: 2021-10-04 (Crawled : 11:00) - biospace.com/
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: 2.16%
H: 1.33%
C: -4.36%
food fda drug license biosimilar
Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review
Published: 2021-10-01 (Crawled : 20:00) - biospace.com/
ABBV | $162.93 0.78% 3.1M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
fda biosimilar
Junshi Biosciences and Coherus Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
Published: 2021-09-01 (Crawled : 13:00) - globenewswire.com
ABBV | $162.93 0.78% 3.1M
|
Health Technology
|
| O: 0.18%
H: 0.44%
C: -7.21%
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: -0.13%
H: 1.75%
C: 1.0%
treatment fda submission bla submission
Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
Published: 2021-09-01 (Crawled : 12:15) - globenewswire.com
ABBV | $162.93 0.78% 3.1M
|
Health Technology
|
| O: 0.18%
H: 0.44%
C: -7.21%
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: -0.13%
H: 1.75%
C: 1.0%
treatment fda submission bla submission
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
Published: 2021-08-12 (Crawled : 12:15) - globenewswire.com
ABBV | $162.93 0.78% 3.1M
|
Health Technology
|
| O: 0.21%
H: 1.55%
C: 1.47%
CHRS | $2.155 -2.05% -2.09% 1.4M
|
Health Technology
|
| O: 1.05%
H: 1.26%
C: 0.96%
treatment fda therapy breakthrough therapy grant designation
Gainers vs Losers
| 53% | 47% |
Top 10 Gainers
WISA 4 | $5.33 204.57% 190M
|
Electronic Technology
SXTC | $1.78 52.14% 33M
|
Health Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
BSGM | $1.52 38.18% 3.2M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
VIAO | $0.2426 -21.23% 230K
|
Electronic Technology
BACK | $4.53 35.22% 26.05% 950K
|
Health Care and Social Assistan...
Your saved searches
Save your searches and get alerts when important news are released.